CPEB4 is a candidate biomarker for defining metastatic cancers and directing personalized therapies

Medical Hypotheses

Volumn 81, Issue 5, 2013, Pages 875-877

  Xu, Huiyu ^a   Liu, Bing ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; CYTOPLASMIC POLYADENYLATION ELEMENT BINDING PROTEIN; CYTOPLASMIC POLYADENYLATION ELEMENT BINDING PROTEIN 4; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HYPOTHESIS; METASTASIS; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; TUMOR INVASION;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886793502     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.08.030     Document Type: Article

References (8)

1. Ortiz-Zapater E., Pineda D., Martinez-Bosch N., Fernandez-Miranda G., Iglesias M., Alameda F., et al. Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med 2012, 18(1):83-90.
2. D'Ambrogio A., Nagaoka K., Richter J.D. Translational control of cell growth and malignancy by the CPEBs. Nat Rev Cancer 2013, 13(4):283-290.
3. Barrett T., Troup D.B., Wilhite S.E., Ledoux P., Evangelista C., Kim I.F., et al. NCBI GEO: archive for functional genomics data sets-10years on. Nucleic Acids Res 2011, 39(Database issue):D1005-D1010.
4. Rustici G., Kolesnikov N., Brandizi M., Burdett T., Dylag M., Emam I., et al. ArrayExpress update-trends in database growth and links to data analysis tools. Nucleic Acids Res 2013, 41(Database issue):D987-D990.
5. Chang J.T., Nevins J.R. GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 2006, 22(23):2926-2933.
6. Hagenbuchner J., Kuznetsov A.V., Obexer P., Ausserlechner M.J. BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene 2012, 12(10).
7. Huang G.S., Brouwer-Visser J., Ramirez M.J., Kim C.H., Hebert T.M., Lin J., et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 2010, 16(11):2999-3010.
8. Davis A.P., Murphy C.G., Johnson R., Lay J.M., Lennon-Hopkins K., Saraceni-Richards C., et al. The comparative toxicogenomics database: update 2013. Nucleic Acids Res 2013, 41(Database issue):D1104-D1114.